西安市妇科门诊患者HPV和HPV疫苗的认知调查

目的 了解西安市妇科门诊患者对人乳头瘤病毒(HPV)的认知情况及其接种HPV疫苗的态度,为推广HPV疫苗的接种提供依据. 方法 在西安市第四医院妇科门诊单纯随机抽取前来就诊的患者1 000人,采用自行设计的问卷,进行调查.问卷内容主要包括患者的基本资料(年龄、婚姻、学历、职业)、对HPV的认知、对HPV疫苗的认知及态度. 结果 32.5％患者知晓HPV,不同年龄、教育程度、职业的女性在HPV知晓率上差异均有统计学意义.30＜年龄≤40岁年龄段的女性对HPV的知晓率(49％)明显高于21≤年龄≤30岁(34.4％)和60＜年龄≤71岁(17.6％)年龄段的女性,大学及以上学历的女性对HPV的知晓率(44.3％)明显高于初高中组,未受过教育的女性对HPV的知晓率(29.7％)最低;干部/职员/技术人员对HPV的知晓率(41.7％)最高,而工人、农民、个体户/服务人员对HPV的知晓率普遍偏低.76.0％患者愿意接种HPV疫苗,担心会感染HPV(32.1％)或患宫颈癌(26.1％)的女性有较强的接种意愿.56.6％的患者能接受的疫苗价格在50 ～ 100元,有49.9％的患者更愿意接受政府提供的疫苗,40.8％的患者更愿意接受医疗机构提供的疫苗. 结论 西安市门诊患者对HPV及其疫苗的知晓率较低,应加强公众健康教育宣传力度,普及HPV疫苗相关知识.     

Knowledge of human papillomavirus (HPV) and HPV vaccination: An international comparison

Since vaccination against human papillomavirus (HPV) became available, awareness of HPV has dramatically increased. Implementation of a vaccine program varies internationally yet no studies have explored the influence this has on the public's knowledge of HPV. The present study aimed to explore differences in awareness of HPV and HPV knowledge across three countries: The US, UK and Australia.     

Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda

Background

Investigations of vaccine efficacy and immunogenicity for adult females receiving fewer than three doses of human papillomavirus (HPV) vaccine have suggested protection against infection and precancerous lesions. We investigated the immunogenicity of bivalent HPV vaccines among adolescent girls from Uganda who received one, two, or three vaccine doses.

Methods

Young girls vaccinated through a government program in Uganda were invited to participate. HPV16- and HPV18-specific antibodies were measured at ≥24 months after the last vaccine dose using an enzyme linked immunoassay in girls who received one (n = 36), two (n = 145), or three (n = 195) doses.

Results

Nearly all subjects (99%) were HPV16 and HPV18 seropositive at the time of blood-draw. Geometric mean antibody levels (GMTs) were: HPV16_1-dose = 230 EU/mL, HPV16_2-dose = 808 EU/mL, and HPV16_3-dose = 1607 EU/mL; HPV18_1-dose = 87 EU/mL, HPV18_2-dose = 270 EU/mL, and HPV18_3-dose = 296 EU/mL. The GMT ratio for 2:3 doses was 0.50 (HPV16) and 0.68 (HPV18) and did not meet the non-inferiority criteria (i.e., lower bound of 97.5% confidence interval of the GMT ratio greater than 0.50). The GMT ratio for 1:3 doses for HPV16 and HPV18 was inferior, but absolute GMTs for one dose were higher than adult women who received one dose (HPV16 = 124 EU/mL, HPV18 = 69 EU/mL) where efficacy has been demonstrated.

Conclusions

Even though immunogenicity with less than three doses did not meet a priori non-inferiority thresholds, antibody levels measured ≥24 months after last dose were similar to those of adult women who have been followed for more than eight years for efficacy.     

HPV vaccine acceptability among Kenyan women

As human papillomavirus (HPV) vaccines become available in less-developed countries, understanding women's attitudes towards HPV vaccines can help guide approaches to immunization programs. We assessed knowledge and interest in prophylactic HPV vaccines among Kenyan women seeking women's health services (N = 147). They knew little about cervical cancer or HPV vaccine. Most women (95%, 95% confidence interval [CI]: 92%, 99%), however, were willing to have their daughters vaccinated with a vaccine that would prevent cervical cancer, with preference for an inexpensive vaccine requiring fewer doses.     

Perceptions and acceptability of HPV vaccination among parents of young adolescents: A multicenter national survey in China

Prophylactic HPV vaccines target young adolescents to prevent related cervical lesions and even genital warts prior to onset of sexual activity. Parental consent is often essential for success of vaccination program for this age group. We conducted a national multicenter study to explore the acceptability of HPV vaccination among parents of young adolescents and associated factors in relevant parent decision making in China. A total of 2899 parents of young adolescents (11–17 years) participated in the survey between November 28, 2011 and May 9, 2012, but four were excluded from analysis because of inconsistencies in their given information in the questionnaire. Mothers accounted for 62.8% of the parent participants. The mean age of the parents was 40.40 (standard deviation, 4.68) years. Only 36.2% of the parents accepted the vaccine for their children. Knowledge about HPV and HPV vaccine was a positive correlate with HPV vaccination acceptability (P_trend = 0.003). Grade of child (P_trend = 0.015), prior vaccination experience outside the National Expanded Program on Immunization (OR: 1.43; 95%CI: 1.19–1.72), fear of cervical cancer and/or genital warts (OR: 2.47; 95%CI: 2.00–3.05), and prior consultation regarding HPV vaccine information (OR: 2.35; 95%CI: 1.57–3.52) were also positively associated with higher HPV vaccine acceptability. The acceptability was lower in mothers (OR: 0.45; 95%CI: 0.37–0.54) and who had better education (P_trend = 0.009). 57.3% of the parents agreed that the most appropriate venue for HPV vaccination was the local center for disease prevention and control. In conclusion, our study indicates a low acceptability of HPV vaccination among parents of young adolescents in China. We understand there are many challenges in implementing HPV vaccination program. Our findings will serve as valuable references for future HPV vaccination policies and campaigns after HPV vaccines are approved in China.     

Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: Results from a longitudinal Dutch cohort study

IntroductionBecause of the long interval between infection with high-risk human papillomavirus (hrHPV) and development of cervical cancer surrogate markers for cancer incidence are necessary to monitor vaccine effectiveness (VE). The aim of this study was to calculate VE of HPV16/18 vaccination by annually assessing incident and persistent infections among (un)vaccinated girls from the general Dutch population up to 3 years after vaccination.MethodsIn 2009, 1668 girls (54% vaccinated) aged 14–16 years were enrolled in a prospective cohort study. Annually, questionnaire data were obtained, and a vaginal swab was tested for type-specific HPV DNA with SPF₁₀-LiPA. VE was estimated by a Poisson model comparing type-specific infection rates in (un)vaccinated girls.ResultsThe adjusted VE (95% CI) was 73% (49–86%) against incident infections with HPV16/18 and 72% (52–84%) against HPV16/18/31/45. VE against persistent HPV16/18 was 100% and 76% (−17 to 95%) against HPV16/18/31/45. This number was lower (36%) when girls who were positive for HPV16 and 18 at baseline were included in the analysis. The overall VE for hrHPV types combined was small. Although 96% of girls were HPV-naïve at baseline, the cumulative 36-month incidence for any HPV was 20%, indicating high sexual activity.DiscussionVaccination is effective against incident and persistent infections with HPV16/18 and HPV16/18/31/45. Low VE against persistent HPV16/18 infection in girls positive at baseline indicates importance of vaccination before sexual debut.     

Knowledge,attitudes, and practices among Saudi women regarding cervical cancer,human papillomavirus (HPV) and corresponding vaccine

AimTo our knowledge there are no studies exploring Saudi women’s understanding of the importance of the human papillomavirus (HPV) vaccine. In the present study, we examined the awareness of HPV and women’s attitudes toward the HPV vaccine.MethodNine focus groups were formed in Riyadh City, Saudi Arabia, including 77 women between the ages of 18 and 45 years old. Face-to-face interviews were conducted in 58 female healthcare providers to examine women’s awareness of cervical cancer, HPV, barriers, acceptance, beliefs, and attitudes towards the HPV vaccine.ResultsFocus group discussions revealed a lack of knowledge and awareness of cervical cancer, HPV, and the HPV vaccine. Cultural concerns regarding screening and vaccinating for a conventionally known sexually transmitted infection were an emerging theme in addition to not perceiving cervical cancer screening as necessary because women with no signs and symptoms considered themselves not at risk for developing cervical cancer. Approximately 30% of healthcare providers other than physicians were unaware of prevention methods, and 63.3% did not practice any screening methods for cervical cancer and attributed the lack of screening to “no specific reasons at all”.ConclusionBecause of the unfavorable knowledge and attitude of HPV infection and the associated vaccine from the women in the present study, emphasis should be directed to educate and promote awareness of women to the risk factors of cervical cancer and to the need for screening programs and the administration of the vaccine.     

杭州市女性人类乳头瘤病毒疫苗认知度及接受度的调查研究

目的调查杭州市女性对人类乳头瘤病毒(human papillomavirus,HPV)疫苗的认知度以及接受度,为HPV疫苗的推广提供一定的基础。方法以问卷的形式对500名在杭女性进行HPV疫苗认知度以及接受度的调查,将数据结果统计分析。结果 500名调查对象中只有28.83%知道HPV疫苗相关知识,在杭女性HPV疫苗的认知度与年龄和教育程度有关,不同年龄女性认知度间差异有统计学意义(P<0.05),不同学历女性认知度间差异有统计学意义(P<0.05)且认知度随着受教育程度的提高而增加。受调查者中,有47.85%的女性愿意接受HPV疫苗。结论在杭女性对HPV疫苗的认知度和接受度均不高,因此应加强这方面的教育,有利于促进宫颈癌综合防治工作。     

Acceptance of the HPV vaccine among women,parents, community leaders,and healthcare providers in Ohio Appalachia

To assess HPV vaccine acceptability, focus groups of women (18–26 years), parents, community leaders, and healthcare providers were conducted throughout Ohio Appalachia. Themes that emerged among the 23 focus groups (n = 114) about the HPV vaccine were: barriers (general health and vaccine specific), lack of knowledge (cervical cancer and HPV), cultural attitudes, and suggestions for educational materials and programs. Important Appalachian attitudes included strong family ties, privacy, conservative views, and lack of trust of outsiders to the region. There are differences in HPV vaccine acceptability among different types of community members highlighting the need for a range of HPV vaccine educational materials/programs to be developed that are inclusive of the Appalachian culture.     

甘肃宫颈癌高发区女性HPV及其疫苗认知状况调查

目的调查甘肃省宫颈癌高发地区陇南市武都区女性对人乳头瘤病毒（HPV）的认知及对HPV疫苗接种的态度情况。方法采用随机整群抽样的方法抽取武都区2个乡,其中符合筛选条件的30—49岁女性1681人,使用问卷调查女性对HPV认知情况和接种HPV疫苗的态度。结果接受调查女性中1585人（94．29％）没有听说过HPV,但有1584人（94．23％）愿意接受HPV疫苗接种;40岁以下人群对HPV疫苗接种的接受程度明显高于40岁以上人群（P〈0．01）;女性对HPV知晓率与所受教育程度和家庭收入呈正相关（P〈0．01）;调查女性不愿意接种HPV疫苗的原因主要是对宫颈癌的风险意识不足;调查人群中有637人愿意接受医疗机构提供的HPV疫苗,972人接受政府提供的,两项合计占总调查人数的95．71％;有74．84％的人希望国家能够负担部分接种HPV疫苗的费用;本次调查女性中有131人（7．79％）HPV检测呈阳性,HPV感染与未感染女性在HPV认知及其疫苗相关态度调查结果基本一致。结论甘肃省陇南市武都区女性缺乏对宫颈癌和HPV的认知,但是对HPV疫苗的信任和接受程度很高,因此急需通过多种方式加强对陇南地区女性宫颈癌相关科普知识的普及以及改善当地居民生活水平。     

HPV vaccination among a community sample of young adult women

Objectives

Despite the high efficacy of the human papillomavirus (HPV) vaccine, uptake has been slow and little data on psychosocial barriers to vaccination exist.

Methods

A community sample of 428 women enrolled in a longitudinal study of social development in the Seattle WA metropolitan area were interviewed about HPV vaccine status, attitudes, and barriers to HPV vaccination in spring 2008 or 2009 at ∼age 22.

Results

Nineteen percent of women had initiated vaccination, 10% had completed the series, and ∼40% of unvaccinated women intended to get vaccinated. Peer approval was associated with vaccine initiation (adjusted prevalence ratio (APR) 2.1; 95% confidence interval 1.4-3.2) and intention to vaccinate (APR 1.4; 1.1-1.9). Belief the vaccine is <75% effective was associated with less initiation (APR 0.6; 0.4-0.9) or intention to vaccinate (APR 0.5; 0.4-0.7). Vaccine initiation was also less likely among cigarette smokers and illegal drug users, whereas intention to vaccinate was more common among women currently attending school or with >5 lifetime sex partners, but less common among women perceiving low susceptibility to HPV (APR 0.6; 0.5-0.9).

Conclusions

HPV vaccination uptake was low in this community sample of young adult women. Increasing awareness of susceptibility to HPV and the high efficacy of the vaccine, along with peer interventions to increase acceptability, may be most effective.     

Disparities in parental human papillomavirus (HPV) vaccine awareness and uptake among adolescents

Trends in HPV vaccine awareness among parents of adolescent girls and boys (ages 13–17) and HPV vaccine uptake (≥1 dose) among girls (ages 13–17) were evaluated in Los Angeles County, California. Between 2007 and 2011, parental HPV vaccine awareness increased from 72% to 77% overall, with significant increases among mothers, Latinos, and respondents with daughters and Medi-Cal insured children. In 2011, parents who were male, older, less educated, Asian/Pacific Islander, and had sons remained significantly less likely to be aware. HPV vaccine initiation among daughters nearly doubled from 25% in 2007 to 48% in 2011, and girls who were older, uninsured, and had access-related barriers showed the largest improvements. In 2011, daughters who were younger and who had older and African American parents were at risk for low uptake. Thus, initiatives targeting male and younger adolescents, culturally-relevant information, and access to vaccination may help to reduce identified disparities.     

不同年龄组妇女HPV感染流行病学研究

目的:了解不同年龄组妇女人类乳头瘤病毒(HPV)感染状况及子宫颈癌前病变或子宫颈癌发病情况,为子宫颈癌防治提供依据。方法:整群抽样调查深圳市福田区教育系统女性职工,并进行HPV感染检测及子宫颈癌与癌前病变流行病学调查,评价不同年龄组妇女HPV感染及子宫颈癌前病变或子宫颈癌检出情况。结果:纳入研究的健康妇女2 052例,HPV阳性率12.03%,C INⅠ以上病变检出率1.71%;HPV阳性率高峰年龄在<30岁及40～44岁年龄组,阳性率分别为13.40%和14.70%;35～44岁年龄组C INⅠ以上病变检出率2.28%,显著高于其他年龄组,差异具有统计学意义(P<0.05)。结论:30岁以下年轻妇女高危型HPV阳性多为一过性感染,不推荐HPV检测作为年龄<30岁妇女的子宫颈癌前病变或子宫颈癌的筛查方案,子宫颈防治的重点人群应是35岁以上的妇女。     

Factors associated with human papillomavirus vaccination among young adult women in the United States

Background

Human papillomavirus (HPV) vaccination is recommended to protect against HPV-related diseases.

Objective

To estimate HPV vaccine coverage and assess factors associated with vaccine awareness, initiation and receipt of 3 doses among women age 18–30 years.

Methods

Data from the 2010 National Health Interview Survey were analyzed to assess associations of HPV vaccination among women age 18–26 (n = 1866) and 27–30 years (n = 1028) with previous HPV exposure, cervical cancer screening and selected demographic, health care and behavioral characteristics using bivariate analysis and multivariable logistic regression.

Results

Overall, 23.2% of women age 18–26 and 6.7% of women age 27–30 years reported receiving at least 1 dose of HPV vaccine. In multivariable analyses among women age 18–26 years, not being married, having a regular physician, seeing a physician or obstetrician/gynecologist in the past year, influenza vaccination in the past year, and receipt of other recommended vaccines were associated with HPV vaccination. One-third of unvaccinated women age 18–26 years (n = 490) were interested in receiving HPV vaccine. Among women who were not interested in receiving HPV vaccine (n = 920), the main reasons reported included: not needing the vaccine (41.3%); concerns about safety of the vaccine (12.5%); not knowing enough about the vaccine (11.9%); not being sexually active (8.2%); a doctor not recommending the vaccine (7.6%); and already having HPV (2.7%). Among women with health insurance, 10 or more physician contacts within the past year and no contraindications, 74.5% reported not receiving HPV vaccine.

Conclusions

HPV vaccination coverage among women age 18–26 years remains low. Opportunities to vaccinate are missed. Healthcare providers can play an important role in educating young women about HPV and encouraging vaccination. Successful public health and educational interventions will need to address physician attitudes and practice patterns and other factors that influence vaccination behaviors.     

HPV cervical infections and serological status in vaccinated and unvaccinated women

Understanding genital infections by Human papillomaviruses (HPVs) remains a major public health issue, especially in countries where vaccine uptake is low. We investigate HPV prevalence and antibody status in 150 women (ages 18 to 25) in Montpellier, France. At inclusion and one month later, cervical swabs, blood samples and questionnaires (for demographics and behavioural variables) were collected. Oncogenic, non-vaccine genotypes HPV51, HPV66, HPV53, and HPV52 were the most frequently detected viral genotypes overall. Vaccination status, which was well-balanced in the cohort, showed the strongest (protective) effect against HPV infections, with an associated odds ratio for alphapapillomavirus detection of 0.45 (95% confidence interval: [0.22;0.58]). We also identified significant effects of age, number of partners, body mass index, and contraception status on HPV detection and on coinfections. Type-specific IgG serological status was also largely explained by the vaccination status. IgM seropositivity was best explained by HPV detection at inclusion only. Finally, we identify a strong significant effect of vaccination on genotype prevalence, with a striking under-representation of HPV51 in vaccinated women. Variations in HPV prevalence correlate with key demographic and behavioural variables. The cross-protective effect of the vaccine against HPV51 merits further investigation.     

High-risk HPV prevalence among women undergoing cervical cancer screening: Findings a decade after HPV vaccine implementation in British Columbia,Canada

BackgroundBritish Columbia (BC) introduced a publicly funded, school-based human papillomavirus (HPV) immunization program in 2008 with the quadrivalent vaccine. In 2010/2011, a baseline evaluation of HPV prevalence was conducted among women undergoing cervical cancer screening. After 10 years of publicly funded HPV vaccination, HPV-type prevalence was re-evaluated.MethodsFrom August 2017 to March 2018, 1107 physicians were invited to return cytobrushes used during routine Pap screening to the Cervical Cancer Screening Laboratory for HPV testing. Only age or year of birth was collected. Specimens were screened for high-risk HPV (hrHPV) and positive samples were genotyped. HPV type prevalence was compared for females 15–22 yrs (those eligible for the school-based vaccination) and 23+ yrs (ineligible for school-based vaccination) for the 2010/2011 and the 2017/2018 data.ResultsThere were 3309 valid samples received for testing; of these, 3107 were included in the analysis. The overall hrHPV prevalence was 12.2% (95% CI 11.3–13.3) in 2010/11, and 12.0% (95% CI 10.9–13.2) in 2017/18. For the 15–22 age group, the prevalence for any hrHPV was 26.8% (95% CI 23.1–30.8) in 2010/11 and 25.4% (95% CI 15.3–37.9) in 2017/18. For those aged 15–22, HPV16 prevalence in 2010/11 was 8.8% (95% CI 6.5–11.5) and in 2017/18 was 6.3% (95% CI 1.8–15.5), with corresponding figures for HPV18 3.7% (95% CI 2.3–5.7) and 0% (95% CI 0.0–5.7), respectively. For all hrHPV types, there were no statistically significant differences between the 2010/11 and 2017/18 periods.ConclusionsThis study illustrates the prevalence of hrHPV in BC over time in women undergoing cervical cancer screening, where an indication of a decline in HPV16/18 is seen in vaccine eligible women.     

Estimating the long-term effects of HPV vaccination in Germany

In Germany, vaccination against the most oncogenic HPV types 16/18 is recommended by the Standing Committee on Vaccination (STIKO) for 12–17 year old girls since March 2007. We developed a dynamic mathematical model for the natural history and transmission of HPV infections to estimate the impact of vaccination on incidence and mortality of cervical cancer and its pre-stages, and on anogenital warts. We focused on an extensive model calibration to epidemiologic data for all stages of the natural history model as well as on a detailed implementation of cervical cancer screening modalities in Germany. Our model predicts first a substantial reduction of cervical cancer incidence and mortality over the next 30 years, which is mainly attributable to an increase in screening participation in the 1990s and not to HPV vaccination, followed by a further reduction attributable to vaccination. Over the next 100 years, HPV vaccination will prevent approximately 37% of cervical cancer cases even if vaccination coverage is only 50% (as currently observed in Germany). Consideration of cross-protection results in a further reduction of approximately 7% of all cervical cancer cases for the bivalent and about 5% for the quadrivalent vaccine in our model. Vaccination of boys was only reasonable if moderate to high vaccination coverage in girls was not achieved. Strategies should be implemented in Germany to increase HPV vaccination coverage among girls thereby making better use of the demonstrated benefits of the vaccine.     

北京地区6339例25～54岁已婚妇女宫颈癌认知度调查研究

目的了解北京地区已婚妇女宫颈癌认知程度及相关影响因素,为宫颈癌健康教育提供依据。方法采用多阶段整群抽样方法,抽取北京市区、近郊8个区、远郊4个区县6339例已婚妇女,对其宫颈癌的认知程度及相关影响因素进行问卷式调查。结果知道宫颈癌能够早期筛查诊断的为52.5%;认知度与年龄、文化程度、职业、户籍及经济条件有关,并存在统计学差异（P〈0.01）;知道宫颈癌能够早期筛查诊断的妇女中,通过广播、电视、报纸等了解的最多,占69.7%,通过医生咨询了解的占12.0%;宫颈癌发生的高危因素中,认为是宫颈糜烂引起的最多,为59.1%,认为是人乳头瘤病毒感染的仅为26.9%;知道和不知道宫颈癌能够早期筛查诊断的妇女宫颈病变的发病率间无统计学差异（χ^2=3.97,P=0.41）,认知度不同妇女高危型人乳头瘤病毒感染的发生率也无统计学差异（χ^2=1.66,P=0.20）。结论北京地区已婚妇女对宫颈癌的认知程度偏低,其中对人乳头瘤病毒感染与宫颈癌的关系认识尤为不足。文化程度、经济条件影响妇女对宫颈癌的认知程度,应根据人员不同情况采取不同形式与渠道进行宫颈癌健康教育。     

Uptake of HPV Vaccine among young adults with disabilities, 2011 to 2018

IntroductionLittle is known about human papillomavirus (HPV) vaccine uptake among young adults with disabilities (YAWD), despite this population having a higher risk of HPV infection and related cancers compared to the general population.ObjectiveTo compare the prevalence of HPV vaccination among young adults with disabilities to young adults without disabilities. We hypothesized that YAWD would have a lower prevalence of HPV vaccination than the general population.MethodsThis cross-sectional study used data for the years 2011 to 2018 of the National Health Interview Survey. Our analysis included 14,577 people (weighted n = 34,420,024) aged 18 to 26 years. Univariate and multivariable logistic models were used to estimate the role of disability on HPV vaccination uptake among young adults and to identify potential factors associated with HPV vaccination among YAWD.ResultsThe proportion of female and male YAWD with HPV vaccination was similar to those without disabilities, regardless of sex (Female Adjusted Odds Ratio (OR): 1.16; 95% Confidence Interval (CI): 0.91 to 1.48; Male Adjusted OR: 1.05; 95% CI: 0.69 to 1.60). Among female and male YAWD, the proportion with HPV vaccination was 56.1% and 28.5%, respectively. Other factors significantly associated with HPV vaccination among YAWD included age, country of birth, healthcare utilization, and insurance status.ConclusionsHPV vaccination among YAWD did not differ significantly from those without disabilities; however, the prevalence of HPV vaccination among young adult males and females remains significantly below national goals. Connecting young adults, specifically male YAWD, to the healthcare system is of utmost importance to improve HPV vaccination uptake.     

Knowledge and attitudes about human papillomavirus (HPV) and HPV vaccines among women living in metropolitan and rural regions of China

Infection with the human papillomavirus (HPV) is one of the most common sexually transmitted infections and causes virtually all cervical cancer globally. The recent development of two safe and clinically effective vaccines against HPV is a promising step towards lowering cervical cancer rates in the future. What Chinese women think about HPV and the vaccines remains unknown. We undertook a population-based survey, which was embedded in a cervical cancer screening project and was designed to assess women's knowledge about HPV and their acceptability to the vaccines. We found that only 15.0% of women in our study reported to have ever heard of HPV, and this knowledge differs by rural (9.3%) and metropolitan areas (21.6%) and also by education. Most (84.6%) participants were willing to be vaccinated if HPV vaccine became available to them. The present study documents ways in which women learn about HPV and indicates the potential barriers and success of introducing HPV vaccine to China.